New team cleaning up prior teams errors. Strengthen board, reduced costs and focus on higher margin products. They still have many hurdles to over come but they renewed focus and still have three committed large pharma's under contract. Financials still of oncern, but OrbiMed and Amgen ontrolling direction.
Watching Sanofi drug approvals this month. Maybe in a Unilife device.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.